Supernus makes depression drug play with $795m Sage buyout
After Biogen failed with a takeover bid in January, Supernus has swooped in to buy the postpartum depression pill developer.
After Biogen failed with a takeover bid in January, Supernus has swooped in to buy the postpartum depression pill developer.
What's Your Reaction?
